Ranasid Injection (Ranitidine Hydrochloride)

Adult dosage

Administer 50mg of ranitidine as an intravenous or intramuscular injection 3-4 times a day. For intravenous administration, dilute 50mg of this drug in 20ml of normal saline or dextrose solution and administer slowly for at least 2 minutes, or mix in an infusion solution for a 25mg/hr rate over 2 hours. Generally, the effects for upper gastrointestinal bleeding become evident within 1 week; once oral administration is possible, transition to oral dosing.

This medication must be handled with care when cutting the ampoule to avoid glass fragments entering, especially when used on children or the elderly. This medication should not be used in patients with hypersensitivity to its components. Patients with impaired kidney function may experience increased blood concentration as this medication is excreted through the kidneys, necessitating adjustments to dosage or dosing intervals. Caution should be exercised in patients with compromised liver function, hypersensitivity to medications, and elderly patients. Patients with a history of acute porphyria should avoid this medication as it may provoke seizures. This medication may rarely cause severe allergic reactions such as anaphylactic shock; if any unusual symptoms appear during administration, it should be discontinued immediately, and appropriate treatment should be received. Allergic reactions such as urticaria, rash, bronchospasm, and hypotension may occur; if such symptoms appear, use should be discontinued. Various side effects such as blood abnormalities, liver dysfunction, heart rhythm abnormalities, gastrointestinal symptoms, and neurological abnormalities have been reported rarely; immediate consultation with healthcare providers is advised if symptoms occur. The risk of pneumonia may increase in elderly patients or those with chronic illnesses, requiring careful monitoring. This medication may interact with other drugs, so it is crucial to inform healthcare providers of any currently taken medications. Women who are pregnant or breastfeeding should use this medication cautiously as it may affect the fetus or child. Safety in pediatric patients has not been sufficiently established; caution is advised during use. In the event of overdose, symptomatic treatment like vomiting or gastric lavage may be necessary, and if needed, removal via dialysis can be performed. Intramuscular injection may cause pain or hardening at the injection site, which should be noted with caution. For patients concerned about heart rhythm abnormalities, the infusion rate should be controlled slowly. This medication may mask symptoms of gastric cancer, so gastric ulcer patients or those over mid-age with newly appearing dyspeptic symptoms should have malignancy screened prior to treatment. Prolonged use may affect eye health; therefore, careful use with regular ophthalmological examinations is recommended.

Serious side effects

• Urticaria
• angioedema
• shock (anaphylactic shock)
• severe allergic reactions
• vascular swelling
• bronchospasm
• hypotension
• chest pain
• anaphylactic shock
• thrombocytopenia

Mild side effects

• Increased serum creatinine
• constipation
• nausea
• vomiting
• abdominal bloating
• abdominal pain
• loss of appetite
• diarrhea
• dizziness
• drowsiness

This medication should be stored in a sealed container that blocks light, kept at a temperature between 1 to 30 degrees Celsius. Proper storage helps maintain efficacy and prevents degradation.

Appearance

A clear colorless to pale yellow liquid filled in a brown ampoule.

Package unit

2mL*1 ampoule, 50 ampoules